Rocket Doctor Partners with Melanoma Canada to Enhance Skin Cancer Care

Strategic Insights -

Canadian medical AI company Treatment.com AI Inc. has announced a significant partnership between its virtual care subsidiary, Rocket Doctor Inc., and cancer charity Melanoma Canada. This collaboration aims to expand access to follow-up care for individuals identified as at-risk during mobile skin cancer screenings. Patients in Ontario, Alberta, and British Columbia without a family doctor will be directly referred to Rocket Doctor physicians through a digital intake system. This innovative initiative addresses the growing demand for follow-up care in Canada, where skin cancer accounts for one in three cancer diagnoses.

Key Takeaways:

  • Rocket Doctor Inc., a virtual care subsidiary of Treatment.com AI Inc., has partnered with Melanoma Canada to deliver follow-up care for individuals at-risk during skin cancer screenings.
  • The partnership supports Melanoma Canada's Mole Mobile campaign, offering free skin cancer screenings in urban and remote communities.
  • Patients in Ontario, Alberta, and British Columbia without a family doctor will be directly referred to Rocket Doctor physicians through a digital intake system.
  • The agreement commenced on 3 February 2025, with automatic annual renewals.
  • Rocket Doctor branding will appear on Mole Mobile units during the campaign.
  • The tour begins in Toronto and Edmonton and will visit multiple locations throughout October 2025.
  • The initiative addresses a growing demand for follow-up care in Canada, where skin cancer accounts for one in three cancer diagnoses.
  • Melanoma, the deadliest form of skin cancer, is diagnosed in 22 Canadians daily, with three deaths reported each day.

Statistics:

  • Skin cancer now accounts for one in three cancer diagnoses in Canada.
  • Melanoma, the deadliest form of skin cancer, is diagnosed in 22 Canadians daily.
  • Three deaths from melanoma are reported in Canada each day.
  • The Mole Mobile campaign offers free skin cancer screenings in urban and remote communities.

Sources:

  • Treatment.com AI Inc. press release, dated 14 May 2025.
  • M2 EQUITYBITES, dated 20 May 2025.